These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30700860)

  • 1. What is 'LDL cholesterol'?
    Holmes MV; Ala-Korpela M
    Nat Rev Cardiol; 2019 Apr; 16(4):197-198. PubMed ID: 30700860
    [No Abstract]   [Full Text] [Related]  

  • 2. Dyslipidaemia: Is CETP inhibition a viable therapeutic strategy?
    Fernández-Ruiz I
    Nat Rev Cardiol; 2017 Jul; 14(7):382-383. PubMed ID: 28569268
    [No Abstract]   [Full Text] [Related]  

  • 3. Dyslipidaemias in 2017: Atherogenic lipoproteins as treatment targets.
    Catapano AL
    Nat Rev Cardiol; 2018 Jan; 15(2):75-76. PubMed ID: 29336436
    [No Abstract]   [Full Text] [Related]  

  • 4. Editorial: collecting new external evidence for cholesterol management.
    Streja D
    Curr Opin Endocrinol Diabetes Obes; 2016 Apr; 23(2):121-3. PubMed ID: 26863279
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of Evolocumab on Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies.
    Toth PP; Jones SR; Monsalvo ML; Elliott-Davey M; López JAG; Banach M
    J Am Heart Assoc; 2020 Mar; 9(5):e014129. PubMed ID: 32114889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial.
    Taskinen MR; Del Prato S; Bujas-Bobanovic M; Louie MJ; Letierce A; Thompson D; Colhoun HM
    Atherosclerosis; 2018 Sep; 276():124-130. PubMed ID: 30059843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Success, Failure, and Transparency in Biomarker-Based Drug Development: A Case Study of Cholesteryl Ester Transfer Protein Inhibitors.
    Hey SP; Franklin JM; Avorn J; Kesselheim AS
    Circ Cardiovasc Qual Outcomes; 2017 Jun; 10(6):. PubMed ID: 28611186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New joint consensus initiative on quantifying atherogenic lipoproteins.
    Stock JK
    Atherosclerosis; 2018 Dec; 279():97-99. PubMed ID: 30318139
    [No Abstract]   [Full Text] [Related]  

  • 9. CETP inhibition.
    Duriez P
    Lancet; 2007 Dec; 370(9603):1882-3. PubMed ID: 18068495
    [No Abstract]   [Full Text] [Related]  

  • 10. Dyslipidaemia in 2015: Advances in treatment of dyslipidaemia.
    Grundy SM
    Nat Rev Cardiol; 2016 Feb; 13(2):74-5. PubMed ID: 26763537
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world study.
    Hollstein T; Vogt A; Grenkowitz T; Stojakovic T; März W; Laufs U; Bölükbasi B; Steinhagen-Thiessen E; Scharnagl H; Kassner U
    Vascul Pharmacol; 2019 May; 116():8-15. PubMed ID: 30910670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Journey through cholesteryl ester transfer protein inhibition: from bench to bedside.
    Karalis I; Rensen PC; Jukema JW
    Circ Cardiovasc Qual Outcomes; 2013 May; 6(3):360-6. PubMed ID: 23674310
    [No Abstract]   [Full Text] [Related]  

  • 13. Counterpoint: Low-Density Lipoprotein Cholesterol Targets Are Not Needed in Lipid Treatment Guidelines.
    Robinson JG; Ray K
    Arterioscler Thromb Vasc Biol; 2016 Apr; 36(4):586-90. PubMed ID: 26988588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in Japanese patients with dyslipidemia.
    Teramoto T; Daida H; Ikewaki K; Arai H; Maeda Y; Nakagomi M; Shirakawa M; Watanabe Y; Kakikawa T; Numaguchi H; Johnson-Levonas AO; Blaustein RO
    Atherosclerosis; 2017 Jun; 261():69-77. PubMed ID: 28478132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein.
    Reyes-Soffer G; Millar JS; Ngai C; Jumes P; Coromilas E; Asztalos B; Johnson-Levonas AO; Wagner JA; Donovan DS; Karmally W; Ramakrishnan R; Holleran S; Thomas T; Dunbar RL; deGoma EM; Rafeek H; Baer AL; Liu Y; Lassman ME; Gutstein DE; Rader DJ; Ginsberg HN
    Arterioscler Thromb Vasc Biol; 2016 May; 36(5):994-1002. PubMed ID: 26966279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ApoB.
    Sniderman AD; Pencina M; Thanassoulis G
    Circ Res; 2019 May; 124(10):1425-1427. PubMed ID: 31070997
    [No Abstract]   [Full Text] [Related]  

  • 17. Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance With Clinical Outcomes.
    Tardif JC; Rhainds D; Brodeur M; Feroz Zada Y; Fouodjio R; Provost S; Boulé M; Alem S; Grégoire JC; L'Allier PL; Ibrahim R; Guertin MC; Mongrain I; Olsson AG; Schwartz GG; Rhéaume E; Dubé MP
    Circ Cardiovasc Genet; 2016 Aug; 9(4):340-8. PubMed ID: 27418594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C.
    Pencina MJ; D'Agostino RB; Zdrojewski T; Williams K; Thanassoulis G; Furberg CD; Peterson ED; Vasan RS; Sniderman AD
    Eur J Prev Cardiol; 2015 Oct; 22(10):1321-7. PubMed ID: 25633587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ezetimibe + statin: insufficient benefit.
    Prescrire Int; 2016 Oct; 25(175):245-246. PubMed ID: 30645833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computed tomography angiography defined vulnerable plaque in a patient with low high-density lipoprotein cholesterol and subsequent myocardial infarction.
    Rached FH; Rocha VZ; Santos RD; Serrano CV; Caixeta A
    Coron Artery Dis; 2017 Dec; 28(8):712-714. PubMed ID: 28704240
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.